Heterocyclic derivative and pharmaceutical drug
US-9216968-B2 · Dec 22, 2015 · US
Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same
US10537569B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10537569-B2 |
| Application number | US-201615388349-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 22, 2016 |
| Priority date | Dec 27, 2012 |
| Publication date | Jan 21, 2020 |
| Grant date | Jan 21, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and pharmaceutically acceptable solvates thereof, preparation thereof, pharmaceutical compositions containing them and use of the same in the treatment and/or prevention of neurodegenerative diseases.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for delaying the onset of or treating a disease selected from Alzheimer's disease and Parkinson's disease comprising administering to a patient in need thereof a pharmaceutically effective amount of a sulphate salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine or a pharmaceutically acceptable solvate thereof. 2. The method according to claim 1 , wherein the method is for treating a disease, and the disease is Parkinson's disease. 3. The method according to claim 1 , wherein the method is for delaying the onset of a disease, and the disease is Alzheimer's disease. 4. The method according to claim 1 wherein the sulphate salt has Formula II wherein x designates the number of equivalents of sulphuric acid and x is 0.5 to 4, or a pharmaceutically acceptable solvate thereof. 5. The method according to claim 2 wherein the sulphate salt has Formula II wherein x designates the number of equivalents of sulphuric acid and x is 0.5 to 4, or a pharmaceutically acceptable solvate thereof. 6. The method according to claim 3 wherein the sulphate salt has Formula II wherein x designates the number of equivalents of sulphuric acid and x is 0.5 to 4, or a pharmaceutically acceptable solvate thereof. 7. A method according to claim 1 wherein the method is for treating a disease, and the disease is Alzheimer's disease. 8. A method according to claim 1 wherein the method is for delaying the onset of a disease, and the disease is Parkinson's disease. 9. The method according to claim 7 wherein the sulphate salt has Formula II wherein x designates the number of equivalents of sulphuric acid and x is 0.5 to 4, or a pharmaceutically acceptable solvate thereof. 10. The method according to claim 8 wherein the sulphate salt has Formula II wherein x designates the number of equivalents of sulphuric acid and x is 0.5 to 4, or a pharmaceutically acceptable solvate thereof.
Assignees
Inventors
Classifications
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
- C07D235/30Primary
Nitrogen atoms not forming part of a nitro radical · CPC title
- A61K31/496Primary
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title
Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title
condensed with carbocyclic rings, e.g. benzimidazoles · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10537569B2 cover?
- The present invention relates to sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and pharmaceutically acceptable solvates thereof, preparation thereof, pharmaceutical compositions containing them and use of the same in the treatment and/or prevention of neurodegenerative diseases.
- Who is the assignee on this patent?
- Alzprotect, Univ Lille Ii Droit & Sante, Inst Nat Sante Rech Med, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification C07D235/30. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).